Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenuifoliside a
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Not Established For Clinical Use; Studied In Vitro/in Vivo Models Only[5]
01
Overview
Tenuifoliside A is a bioactive oligosaccharide ester isolated from the roots of *Polygala tenuifolia*, a traditional Chinese medicinal plant. It exhibits anti-apoptotic, neuroprotective, and antidepressant-like effects. Mechanistically, Tenuifoliside A promotes neuronal survival and neurite outgrowth by activating the ERK/CREB/BDNF signaling pathway and enhancing phosphorylation of ERK (extracellular signal-regulated kinase), Akt (protein kinase B), and CREB (cyclic AMP response element-binding protein). Its anti-inflammatory activity is mediated through inhibition of the NF-κB and MAPK pathways. Preclinical studies suggest potential for use in depressive disorders and neuroprotection[1][2][4][7][8].
- Other names
- tenuifoliside atfsaα-D-Glucopyranoside 3-O-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-β-D-fructofuranosyl 6-(4-hydroxybenzoate)tenui
02
Targets
CREB (Cyclic AMP response element-binding protein)NTRK2 (Tropomyosin-related kinase receptor type B)MAPK3 (Mitogen-activated protein kinase 1)NF-κBAKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on tenuifoliside a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenuifoliside a.